Hyderabad, India– June 03, 2024: Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in
HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today
– Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) – Alvotech
Hyderabad India; May 3, 2024 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to
Gurugram and Hyderabad, India, April 25, 2024: Nestlé India Limited (BSE : 500790, NSE: NESTLEIND) referred hereafter as “Nestlé India” and Dr. Reddy’s Laboratories Ltd
Asembia’s AXS24 Summit | April 28 – May 2, 2024 Attendees representing the full spectrum of the pharmaceutical supply chain converge annually to build and
• The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a
• In September 2022, Bayer launched the patented drug vericiguat under the brand name Verquvo™ in India. VERQUVO™ (vericiguat) is the first soluble guanylate cyclase stimulator,
• Aurigene.AI is an end-to-end solution for small molecule drug discovery combining AI and ML capabilities with Aurigene’s core expertise in synthesizing and testing the
• Dr. Reddy’s receives exclusive rights to promote and distribute Sanofi’s vaccine brands including well-established paediatric and adult vaccines in India • The partnership continues
